215 related articles for article (PubMed ID: 2253233)
1. Systemic alkalinization inhibits the ability of flavone acetic acid to augment natural killer activity, induce cytokine gene expression, and synergize with interleukin 2 for the treatment of murine renal cancer.
Futami H; Hornung RL; Back TT; Bull R; Gruys E; Wiltrout RH
Cancer Res; 1990 Dec; 50(24):7926-31. PubMed ID: 2253233
[TBL] [Abstract][Full Text] [Related]
2. Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict dose dependency and therapeutic efficacy against murine renal cancer.
Mace KF; Hornung RL; Wiltrout RH; Young HA
Cancer Res; 1990 Mar; 50(6):1742-7. PubMed ID: 1689611
[TBL] [Abstract][Full Text] [Related]
3. Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.
Hornung RL; Back TC; Zaharko DS; Urba WJ; Longo DL; Wiltrout RH
J Immunol; 1988 Nov; 141(10):3671-9. PubMed ID: 2460546
[TBL] [Abstract][Full Text] [Related]
4. Flavone acetic acid directly induces expression of cytokine genes in mouse splenic leukocytes but not in human peripheral blood leukocytes.
Futami H; Eader LA; Komschlies KL; Bull R; Gruys ME; Ortaldo JR; Young HA; Wiltrout RH
Cancer Res; 1991 Dec; 51(24):6596-602. PubMed ID: 1742732
[TBL] [Abstract][Full Text] [Related]
5. Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer.
Wiltrout RH; Boyd MR; Back TC; Salup RR; Arthur JA; Hornung RL
J Immunol; 1988 May; 140(9):3261-5. PubMed ID: 3258894
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo.
Sayers TJ; Wiltrout TA; McCormick K; Husted C; Wiltrout RH
Cancer Res; 1990 Sep; 50(17):5414-20. PubMed ID: 2117482
[TBL] [Abstract][Full Text] [Related]
7. Immunological effects of flavone acetic acid.
Triozzi PL; Rinehart JJ; Malspeis L; Young DC; Grever MR
Cancer Res; 1990 Oct; 50(20):6483-5. PubMed ID: 2208107
[TBL] [Abstract][Full Text] [Related]
8. Induction of multiple cytokine gene expression and IRF-1 mRNA by flavone acetic acid in a murine macrophage cell line.
Eader LA; Gusella L; Dorman L; Young HA
Cell Immunol; 1994 Aug; 157(1):211-22. PubMed ID: 8039245
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory and immunotherapeutic properties of recombinant gamma-interferon and recombinant tumor necrosis factor in mice.
Talmadge JE; Tribble HR; Pennington RW; Phillips H; Wiltrout RH
Cancer Res; 1987 May; 47(10):2563-70. PubMed ID: 3105865
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
[TBL] [Abstract][Full Text] [Related]
11. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM
J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
[TBL] [Abstract][Full Text] [Related]
12. Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown.
Mahadevan V; Malik ST; Meager A; Fiers W; Lewis GP; Hart IR
Cancer Res; 1990 Sep; 50(17):5537-42. PubMed ID: 2386959
[TBL] [Abstract][Full Text] [Related]
13. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
14. Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells.
Aste-Amezaga M; D'Andrea A; Kubin M; Trinchieri G
Cell Immunol; 1994 Jul; 156(2):480-92. PubMed ID: 7912999
[TBL] [Abstract][Full Text] [Related]
15. Effects of biological response modifiers on lung natural killer activity.
Lauzon W; Lemaire I
Immunopharmacol Immunotoxicol; 1991; 13(3):237-50. PubMed ID: 1719060
[TBL] [Abstract][Full Text] [Related]
16. Effects of alpha-difluoromethylornithine and recombinant interferon-alpha 2 on the growth of a human renal cell adenocarcinoma xenograft in nude mice.
Heston WD; Fleischmann J; Tackett RE; Ratliff TL
Cancer Res; 1984 Aug; 44(8):3220-5. PubMed ID: 6430546
[TBL] [Abstract][Full Text] [Related]
17. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
18. IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones.
Tsutsui H; Nakanishi K; Matsui K; Higashino K; Okamura H; Miyazawa Y; Kaneda K
J Immunol; 1996 Nov; 157(9):3967-73. PubMed ID: 8892629
[TBL] [Abstract][Full Text] [Related]
19. Cytokine induction and therapeutic synergy with interleukin-2 against murine renal and colon cancers by xanthenone-4-acetic acid derivatives.
Futami H; Eader L; Back TT; Gruys E; Young HA; Wiltrout RH; Baguley BC
J Immunother (1991); 1992 Nov; 12(4):247-55. PubMed ID: 1477076
[TBL] [Abstract][Full Text] [Related]
20. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2.
Yamada H; Matsumoto S; Matsumoto T; Yamada T; Yamashita U
J Urol; 2000 Aug; 164(2):526-31. PubMed ID: 10893638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
